Pharmacogenetic tests in cancer chemotherapy: What physicians should know for clinical application

Journal of Pathology

Volumn 223, Issue 1, 2011, Pages 15-27

  Lee, Soo Youn ^a,b,c   McLeod, Howard L ^c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c University of North Carolina   (United States)

Author keywords

BRCA1 2; cancer; chemotherapy; clinical application; CYP2D6; DPYD; EGFR; FCGR3A; KRAS; pharmacogenetics; pharmacogenomics; TYMS; UGT1A1

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA1 PROTEIN; BRCA2 PROTEIN; CD16 ANTIGEN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DIHYDROPYRIMIDINE DEHYDROGENASE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; K RAS PROTEIN; MATUXIMAB; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OXALIPLATIN; PANITUMUMAB; PLATINUM DERIVATIVE; PREDNISONE; RITUXIMAB; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; VINCRISTINE;

3' UNTRANSLATED REGION; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ASIAN; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CAUCASIAN; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TARGETING; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HOMOZYGOSITY; HOT FLUSH; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; METASTASIS; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHARMACOGENETICS; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CYTOCHROME P-450 CYP2D6; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; HUMANS; NEOPLASMS; PHARMACOGENETICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAMOXIFEN;

EID: 78650009798     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2766     Document Type: Review

References (106)

1. Lenz HJ,. Pharmacogenomics and colorectal cancer. Ann Oncol 2004; 15: iv173-177.
2. Popat S, Matakidou A, Houlston RS,. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529-536.
3. Libra M, Navolanic PM, Talamini R, et al., Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy. BMC Cancer 2004; 4: 11.
4. Aschele C, Debernardis D, Casazza S, et al., Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17: 1760-1770.
5. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al., Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001; 1: 65-70.
6. Lecomte T, Ferraz JM, Zinzindohoue F, et al., Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-5888.
7. Mandola MV, Stoehlmacher J, Zhang W, et al., A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004; 14: 319-327.
8. Cho HJ, Park YS, Kang WK, et al., Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007; 29: 190-196.
9. Allen WL, Johnston PG,. Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. Pharmacogenomics 2005; 6: 603-614.
10. Longley DB, Allen WL, Johnston PG,. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Biochim Biophys Acta 2006; 1766: 184-196.
11. Ichikawa W, Takahashi T, Suto K, et al., Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12: 3928-3934.
12. Schwab M, Zanger UM, Marx C, et al., Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138.
13. Mattison LK, Soong R, Diasio RB,. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002; 3: 485-492.
14. Milano G, Etienne MC, Pierrefite V, et al., Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999; 79: 627-630.
15. Johnson MR, Hageboutros A, Wang K, et al., Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 1999; 5: 2006-2011.
16. Wei X, McLeod HL, McMurrough J, et al., Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610-615.
17. Raida M, Schwabe W, Hausler P, et al., Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001; 7: 2832-2839.
18. Morel A, Boisdron-Celle M, Fey L, et al., Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895-2904.
19. Fernandez-Salguero PM, Sapone A, Wei X, et al., Lack of correlation between phenotype and genotype for the polymorphically expressed dihydropyrimidine dehydrogenase in a family of Pakistani origin. Pharmacogenetics 1997; 7: 161-163.
20. Etienne MC, Chatelut E, Pivot X, et al., Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis. Eur J Cancer 1998; 34: 92-97.
21. Smorenburg CH, Peters GJ, van Groeningen CJ, et al., Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluorouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17: 35-42.
22. Omura K,. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int J Clin Oncol 2003; 8: 132-138.
23. van Kuilenburg AB, Muller EW, Haasjes J, et al., Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14 + 1G > A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-1153.
24. Ciccolini J, Mercier C, Evrard A, et al., A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit 2006; 28: 678-685.
25. Deporte-Fety R, Picot M, Amiand M, et al., High-performance liquid chromatographic assay with ultraviolet detection for quantification of dihydrofluorouracil in human lymphocytes: application to measurement of dihydropyrimidine dehydrogenase activity. J Chromatogr B Biomed Sci Appl 2001; 762: 203-209.
26. 13C]dihydrouracil. Clin Cancer Res 2006; 12: 549-555.
27. Bocci G, Barbara C, Vannozzi F, et al., A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther 2006; 80: 384-395.
28. Innocenti F, Ratain MJ,. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006; 7: 1211-1221.
29. Ando Y, Saka H, Ando M, et al., Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6926.
30. Toffoli G, Cecchin E, Corona G, et al., The role of UGT1A1 Ã - 28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-3068.
31. Minami H, Sai K, Saeki M, et al., Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1 à - 6 and à - 28. Pharmacogenet Genomics 2007; 17: 497-504.
32. Deeken JF, Figg WD, Bates SE, et al., Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007; 18: 111-126.
33. Liu JY, Qu K, Sferruzza AD, et al., Distribution of the UGT1A1 Ã - 28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 2007; 18: 693-696.
34. Hahn KK, Wolff JJ, Kolesar JM,. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm 2006; 63: 2211-2217.
35. Hoskins JM, Goldberg RM, Qu P, et al., UGT1A1 Ã - 28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290-1295.
36. Jin Y, Desta Z, Stearns V, et al., CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
37. Goetz MP, Rae JM, Suman VJ, et al., Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
38. Goetz MP, Kamal A, Ames MM,. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83: 160-166.
39. Bradford LD,. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3: 229-243.
40. Bernard S, Neville KA, Nguyen AT, et al., Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006; 11: 126-135.
41. Ingelman-Sundberg M, Sim SC, Gomez A, et al., Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007; 116: 496-526.
42. Goetz MP, Knox SK, Suman VJ, et al., The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-121.
43. Schroth W, Antoniadou L, Fritz P, et al., Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187-5193.
44. Schroth W, Goetz MP, Hamann U, et al., Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J Am Med Assoc 2009; 302: 1429-1436.
45. Kiyotani K, Mushiroda T, Sasa M, et al., Impact of CYP2D6 Ã - 10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99: 995-999.
46. Lim HS, Ju Lee H, Seok Lee K, et al., Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 3837-3845.
47. Wegman P, Elingarami S, Carstensen J, et al., Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9: R7.
48. Nowell SA, Ahn J, Rae JM, et al., Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249-258.
49. Williams LD, Twaddle NC, Churchwell MI, et al., Quantification of tamoxifen and metabolites and soy isoflavones in human plasma using liquid chromatography with electrospray ionization tandem mass spectrometry. J AOAC Int 2006; 89: 1168-1173.
50. Lim YC, Desta Z, Flockhart DA, et al., Endoxifen (4-hydroxy-N-desmethyl- tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55: 471-478.
51. Capdevila J, Saura C, Macarulla T, et al., Monoclonal antibodies in the treatment of advanced colorectal cancer. Eur J Surg Oncol 2007; 33 (Suppl 2): S24-S34.
52. Mitsudomi T, Yatabe Y,. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 2007; 98: 1817-1824.
53. Toschi L, Cappuzzo F,. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2007; 12: 211-220.
54. Loupakis F, Vasile E, Santini D, et al., EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. Pharmacogenomics 2008; 9: 55-69.
55. Lievre A, Bachet JB, Le Corre D, et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006; 66: 3992-3995.
56. Tsao MS, Sakurada A, Cutz JC, et al., Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133-144.
57. Cappuzzo F, Hirsch FR, Rossi E, et al., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643-655. (Pubitemid 40812628)
58. Mitsudomi T, Kosaka T, Endoh H, et al., Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 2005; 23: 2513-2520.
59. Takano T, Ohe Y, Sakamoto H, et al., Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 6829-6837.
60. Jackman DM, Miller VA, Cioffredi LA, et al., Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009; 15: 5267-5273.
61. Sequist LV, Martins RG, Spigel D, et al., First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008; 26: 2442-2449.
62. Eberhard DA, Johnson BE, Amler LC, et al., Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23: 5900-5909.
63. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al., Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101: 1308-1324.
64. Bean J, Brennan C, Shih JY, et al., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104: 20932-20937.
65. Sartore-Bianchi A, Bencardino K, Di Nicolantino F, et al., Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Target Oncol 2010.
66. Giovannetti E, Zucali PA, Peters GJ, et al., Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib. Mol Cancer Ther 2010; 9: 581-593.
67. Maheswaran S, Sequist LV, Nagrath S, et al., Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008; 359: 366-377.
68. Schneider CP, Heigener D, Schott-von-Romer K, et al., Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from German centers in the TRUST study. J Thorac Oncol 2008; 3: 1446-1453.
69. Moroni M, Veronese S, Benvenuti S, et al., Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286.
70. Sartore-Bianchi A, Moroni M, Veronese S, et al., Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol 2007; 25: 3238-3245.
71. Heinemann V, Stintzing S, Kirchner T, et al., Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35: 262-271.
72. Massarelli E, Varella-Garcia M, Tang X, et al., KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007; 13: 2890-2896.
73. Di Fiore F, Blanchard F, Charbonnier F, et al., Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 2007; 96: 1166-1169.
74. Khambata-Ford S, Garrett CR, Meropol NJ, et al., Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007; 25: 3230-3237.
75. Amado RG, Wolf M, Peeters M, et al., Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634.
76. Allegra CJ, Jessup JM, Somerfield MR, et al., American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
77. Linardou H, Dahabreh IJ, Kanaloupiti D, et al., Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9: 962-972.
78. Bouche O, Beretta GD, Alfonso PG, et al., The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treat Rev 2010; 36 (Suppl 1): S1-S10.
79. Di Nicolantonio F, Martini M, Molinari F, et al., Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
80. Laurent-Puig P, Cayre A, Manceau G, et al., Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27: 5924-5930.
81. Sartore-Bianchi A, Martini M, Molinari F, et al., PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009; 69: 1851-1857.
82. Prenen H, De Schutter J, Jacobs B, et al., PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 2009; 15: 3184-3188.
83. Zhang W, Gordon M, Schultheis AM, et al., FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712-3718.
84. Bibeau F, Lopez-Crapez E, Di Fiore F, et al., Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009; 27: 1122-1129.
85. Cvetkovic RS, Perry CM,. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2006; 66: 791-820.
86. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al., IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-3274.
87. O'Brien SM, Kantarjian H, Thomas DA, et al., Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165-2170. (Pubitemid 32366970)
88. Cartron G, Dacheux L, Salles G, et al., Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002; 99: 754-758.
89. Hatjiharissi E, Xu L, Santos DD, et al., Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V/V and V/F polymorphism. Blood 2007; 110: 2561-2564.
90. Kim DH, Jung HD, Kim JG, et al., FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006; 108: 2720-2725.
91. Nishio M, Endo T, Fujimoto K, et al., FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur J Haematol 2009; 82: 143-147.
92. Carlotti E, Palumbo GA, Oldani E, et al., FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007; 92: 1127-1130.
93. Weng WK, Levy R,. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-3947.
94. Hatjiharissi E, Hansen M, Santos DD, et al., Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma 2007; 7: 286-290.
95. Mitrovic Z, Aurer I, Radman I, et al., FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 2007; 92: 998-999.
96. Golay J, Zaffaroni L, Vaccari T, et al., Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-3908.
97. Harjunpaa A, Junnikkala S, Meri S,. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51: 634-641.
98. Zhang N, Khawli LA, Hu P, et al., Generation of rituximab polymer may cause hyper-cross-linking-induced apoptosis in non-Hodgkin's lymphomas. Clin Cancer Res 2005; 11: 5971-5980.
99. Wang W, Figg WD,. Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance. Cancer Biol Ther 2008; 7: 1004-1005.
100. Tan DS, Rothermundt C, Thomas K, et al., 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008; 26: 5530-5536.
101. Foulkes WD,. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006; 5: 135-142.
102. Wang Y, Cortez D, Yazdi P, et al., BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000; 14: 927-939.
103. Drew Y, Calvert H,. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 2008; 1138: 136-145.
104. Byrski T, Gronwald J, Huzarski T, et al., Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010; 28: 375-379.
105. Sakai W, Swisher EM, Karlan BY, et al., Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008; 451: 1116-1120.
106. Swisher EM, Sakai W, Karlan BY, et al., Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res 2008; 68: 2581-2586.